2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Role of communities in AIDS response

      editorial
      The Indian Journal of Medical Research
      Wolters Kluwer - Medknow

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The world has been experiencing a terrible epidemic of human immunodeficiency virus (HIV) over the last 40 years1. HIV causes progressive immunodeficiency and if untreated almost invariably leads to an AIDS-defining illness and then premature death2. AIDS is an acronym for acquired immune deficiency syndrome; the surveillance definition was proposed by the Centers for Disease Control and Prevention in 1982 to investigate the mystery illnesses first seen in some communities in the USA who had no reason or recognised cause for immunodeficiency3. Very soon after a retrovirus was isolated, accurate diagnostic tests were developed, and the dreadful truth became clear - HIV/AIDS was pandemic with millions of adults and children infected or already dead. Sub-Saharan Africa has always borne the brunt of the epidemic, with around two-thirds of the estimated cases and deaths over the decades. In many African countries and communities, HIV is a generalized epidemic largely spread by sexual intercourse and affecting sexually active men and women alike, with many children becoming infected in utero, during birth or via breast milk. With such community-wide risks and rates of infection, a whole of population response with a public health approach is needed4, which focuses on both prevention and treatment, which promotes behavioural change such as condom use to reduce sexual transmission, adherence counselling in life-long therapy and ways to combat the challenges of stigma and discrimination5. The theme for the World AIDS day this year is that communities make the difference6. The African countries that have done the best to confront HIV and implement successful HIV and AIDS control programmes have had strong political leadership; a vibrant civil society that is non-judgemental but compassionate and engaged communities that expect and often have to demand appropriate resource allocation for all the necessary interventions. Civil society is the sum of community groups7; and the countries that have successfully controlled and reversed the epidemic, have achieved this through strong and cohesive community responses8. The scale of the challenge in South Africa in particular is enormous: unfortunately, some groups miss out on otherwise effective programmes and remain with high levels of infection, morbidity and mortality. Young men and adolescent girls remain particularly vulnerable, despite multiple efforts to target them and implement proven behavioural change, prevention and treatment interventions. Both these groups tend to lack strong community cohesion and representation in national or regional decision-making forums. Lack of community unfortunately perpetuates the epidemic8. In other regions of the world, HIV tends to be more focused in particular communities with specific risk factors, who experience what epidemiologists call a concentrated epidemic. In the USA, where AIDS surveillance was first carried out, it was soon obvious that three communities at least were particularly impacted: homosexuals, individuals of Haitian heritage and haemophiliacs1 3. Of the ‘three Hs’, as they were sometimes initially referred to, haemophiliacs were considered ‘innocent’, whereas Haitian-heritage people were already discriminated against as a poor immigrant community and gay men were blamed for bringing it on themselves with their ‘unnatural’ sexual practices. The gay community responded, as their peers, colleagues and partners wasted away and then died with purpose and with anger. They refused to be blamed, dismissed or further marginalized. Governments across the rich industrialized world, particularly in the USA, could not ignore their collective activism in directly confronting prejudice, stigma and discrimination. Some clinicians were better than others: nurses were usually more empathetic than doctors initially and led the way9. Nor could wider society afford to ignore and dismiss this health emergency, as all could be at risk and die from ignorance. Such activism drove wide-scale awareness campaigns that succeeded when they were non-judgemental and non-stigmatising. Politicians and decision makers were shamed or pressurised to allocate appropriate and sufficient resources to deal with the multiple emerging challenges. The biomedical research community reacted with speed with ring-fenced funding and unprecedented developments were achieved in diagnostics, clinical management and effective therapeutics. The dramatic advances in diagnostics now extend way beyond HIV - for example, with single-patient point-of-care tests, or salivary-based rather than whole blood or serum-based assays10. The speed of drug development is almost unprecedented, with well-tolerated and low-toxicity combination therapy now available in single-pill co-formulations enabling the ‘one-pill-once-daily’ strategy to now be the standard of care for most patients. Recently, this has been extended to effective short-course treatment and cure (in most patients) for hepatitis C infection10. Safe, tolerable antiretroviral combinations have also enabled pre-exposure prophylaxis to be evaluated and implemented-driven by community pressure and taking a lead from malaria and tuberculosis control programmes where chemoprophylaxis has been standard practice for generations. Only the older generations involved with HIV will appreciate just how far and fast we have gone, to me the most powerful example is how communities take responsibility and make a real and lasting difference that impacts all - rich or poor, adult or child, gay or straight. Another consequence of the community activism that emerged as the AIDS epidemic unfurled was the uncomfortable truth - for some clinicians at least - that the patient often knew more than the doctor. This activism confronted the traditional healthcare paradigm and upended the parochial and one-sided clinical consultations that characterized the doctor-patient relationship several decades ago. Younger clinicians may not recognize how revolutionary it was to deal with a patient as an informed equal, and fully involve them in clinical decision-making. Such approaches are now the norm across almost all jurisdictions, to the benefit of all patients in acute or chronic, long-term care. It is particularly relevant with antiretroviral therapy and for non-communicable diseases where there is effective treatment but not cure, and treatment needs therefore, to be lifelong. India has a concentrated epidemic, with significant regional differences in risk profiles and exposed and at-risk communities, only to be expected in such a populous and diverse subcontinent11. HIV/AIDS control programmes do well where there are cohesive communities which receive support to develop and implement targeted interventions. The National AIDS Control Organisation (NACO) has, by international comparisons, been very successful at an aggregate country level in both HIV prevention and treatment12. It has been most successful with behavioural change or delivering antiretroviral therapy when it meaningfully engages with communities most impacted by HIV and which have been encouraged to engage with the NACO and State-level agencies to develop cohesive community responses. In the non-governmental [non-governmental organization (NGO)] sector, the Avahan projects that focus on female sex workers and which have paid special attention to developing significant community engagement and fostering community leadership have been particularly successful13. Neither government-led nor NGO-led programmes have done well where communities struggle with stigma and discrimination and remain marginalized: consider the States, particularly in the northeast where HIV transmission is driven by injecting drug use. Clearly in India as elsewhere, communities make a huge and positive difference where they are included, and failure to develop meaningful interactions inhibits programmatic success11 12. What is the future? With HIV infection, now a chronic, treatable but incurable condition, like many non-communicable diseases such as hypertension or type 2 diabetes, the focus of health systems must be to embrace a universal health care (UHC) approach: to promote relevant behavioural change and lifestyle interventions; to screen at the population level and to implement long-term, lifelong treatment interventions14. These will succeed where communities are engaged and will struggle if they are not actively involved. This is the lesson from HIV: UHC is predicated on recognizing that communities make a difference and without meaningful engagement, it will struggle to succeed.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The natural history of HIV infection

          Purpose of review To review recent published literature around three areas: long-term nonprogression/viral control; predictors of viral load set point/disease progression; and the potential impact of antiretroviral therapy (ART) in early HIV infection. Recent findings The natural course of untreated HIV infection varies widely with some HIV-positive individuals able to maintain high CD4 cell counts and/or suppressed viral load in the absence of ART. Although similar, the underlying mechanistic processes leading to long-term nonprogression and viral control are likely to differ. Concerted ongoing research efforts will hopefully identify host factors that are causally related to these phenotypes, thus providing opportunities for the development of novel treatment or preventive strategies. Although there is increasing evidence that initiation of ART during primary infection may prevent the immunological deterioration which would otherwise be seen in untreated HIV infection, recent studies do not address the longer term clinical benefits of ART at this very early stage. Summary A better understanding of the relative influences of viral, host, and environmental factors on the natural course of HIV infection has the potential to identify novel targets for intervention to prevent and treat HIV-infected persons.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Reorienting health systems to care for people with HIV beyond viral suppression

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Eliminating HIV & AIDS in India: A roadmap to zero new HIV infections, zero discrimination & zero AIDS-related deaths

              The HIV and AIDS epidemic in India: Getting to zero In 2011, the World Health Organization Member States adopted a new global health sector strategy to implement initiatives to reduce HIV prevalence and AIDS-related deaths1. The United Nations Programme on HIV and AIDS (UNAIDS) also targets to end AIDS as a public health threat by 20302. At the end of 2013, India had the third largest number of people living with HIV (PLHIV) in the world and accounted for about four out of ten PLHIV in Asia. There are 2.1 million PLHIV in India, of whom 790,000 are women3. Key populations at very high risk of HIV transmission are men who have sex with men (MSM) and people who inject drugs. These groups are nearly 20-30 folds higher at risk than in the general population (0.3%), closely followed by female sex workers and migrants3. HIV and AIDS response in India India has made a great progress in controlling HIV since the beginning of the epidemic. The National AIDS Control Organization (NACO) realized early on that the western model of specialist physician management and advanced laboratory monitoring was not feasible in India. From 2004 onwards, the NACO set up antiretroviral treatment (ART) centres, which provided one of the world's largest free ART, and HIV testing and counselling sites all across the country. The current programme, National AIDS Control Programme IV (NACP-IV) (2012-2017) is aimed at diagnosing and reducing annual new HIV cases by 50 per cent through comprehensive HIV treatment, education, care and support for the general population and to build on targeted interventions for the key affected groups and those at a high risk of HIV transmission4. The NACO estimated that around 1,300,000 PLHIV needed ART in 20155. Despite this progress, only 43 per cent of adults living with HIV are on ART and only 74 per cent of all PLHIV in India are thought to be aware of their HIV status6 7. Though this is well short of the global ‘90-90-90’ target by the year 2020 (which is, 90% of PLHIV know their status; 90% of diagnosed individuals receiving treatment and 90% treated individuals have an undetectable viral load), but India has successfully achieved the 6th Millennium Development Goal of halting and reversing the HIV epidemic5. Diagnosis of annual new HIV cases in India have declined by more than 50 per cent during the past decade. The six highest prevalence States (Karnataka, Maharashtra, Manipur, Odisha, Andhra Pradesh and Telangana) all have shown a declining trend, in terms of HIV prevalence3. Challenges in meeting the demands of a diverse culture India is a large, socially diverse and complex country, which is a challenge when trying to implement any national medical programme. To widen their reach towards people from different socio-economic backgrounds, targeted interventions supported by the NACO (such as the Project Pehchan, Avahan, Sonagachi Project, Project Kavach, as well as HIV education and awareness through Link Worker Scheme, Red Ribbon Express and The Condom Social Marketing Programme) play innovative roles in financing and providing healthcare services, particularly for the key affected groups and those at high risk of HIV transmission. Community and peer-based approaches to sharing prevention tools and increasing awareness about HIV and AIDS have proven to be effective8. What is now concerning is that the low-prevalence States of Uttarakhand, Assam, Meghalaya, Haryana and Uttar Pradesh show rising trends in the past four years3. Tripura and Sikkim have recorded a relatively steep climb in HIV prevalence3. Given the regional differences in the rates of prevalence of HIV in India, the challenges and solutions for ‘Getting to Zero’ will vary considerably from State to State. HIV pre-exposure prophylaxis in India At the end of 2015, a ‘Pre-Exposure Prophylaxis’ (PrEP) demonstration project was rolled out in Asia's largest red light zone, Sonagachi in Kolkata9 10. The daily use of tenofovir/emtricitabine (Truvada) combination as oral PrEP has been found to be effective in several clinical trials11. PrEP is yet to be introduced across India, and there is no national PrEP policy or guidance at present. However, this ongoing demonstration project can be used to effectively inform the implementation of PrEP all over India. The drugmaker, Cipla received clearance to use generic Truvada for PrEP in early 201612. The next important step will depend on the NACO and inclusion of convenient formulations, such as long-acting injectable antiretrovirals, cabotegravir and rilpivirine, or slow-release dapivirine intravaginal rings, gels as well as more ambitious developments such as subdermal implants and patches in the national programme13. HIV and lesbian gay bisexual transgender criminalization in India After more than a quarter century of the HIV epidemic, it is the considerable burden of stigma that comes with HIV which has shown to create fear about HIV testing and disclosure and drive PLHIV underground with no access to support, treatment or care14. The revival of the 2014 HIV and AIDS Prevention and Control Bill and the Union Cabinet's approval for provisions that makes discrimination against people living with the virus punishable are positive steps towards the ‘Getting to zero’ efforts. The magnitude and nature of the HIV and AIDS epidemic require an environment free of stigma and discrimination to reach the zero goals. Some countries, in particular Australia, are effectively working towards achieving this goal. Australia's strength lies in its public education and management of HIV and AIDS as a public health issue and the understanding and response by all levels of society to the epidemic15. In February 2016, Indian Supreme Court agreed to examine the constitutional validity of Section 377 of the Indian Penal Code that legitimises criminalization of homosexuality16. India's lesbian, gay, bisexual, and transgender community is beginning to gain more recognition and acceptance in the mainstream society. The current need is for interventions that support openness and disclosure and that help protect those with HIV from discrimination and stigma. Taking advantage of India's advances in technology and drug development to fight HIV & AIDS India has emerged as a world leader in the production of generic pharmaceuticals17. Indian generic manufacturers dominate the antiretroviral (ARV) market and have played an exceptional role in providing quality-assured ARVs at low prices to people with HIV and AIDS in developing countries16. However, India continues to battle with antiretroviral drug shortages, one that could derail the impact of the various free interventions and scaled-up prevention strategies being undertaken globally, including the NACP in India. In the HIV landscape, prevention trials on microbicides and vaccines are underway globally. Three phase I HIV vaccine trials have been completed so far by the National AIDS Research Institute in Pune and the National Institute for Research on Tuberculosis in Chennai18 19 20 21. Conducting HIV vaccine trials, especially in countries such as India, requires cooperation and coordination from different segments of society to build the capacity and to conduct clinical trials conforming to ethical framework on par with international standards. India's multidisciplinary approach to fight HIV & AIDS A standardized system with high emphasis on counselling and a multidisciplinary approach present within the public HIV healthcare system will have a positive impact on adherence levels and virological suppression among patients22 23. The general consensus for an effective global approach towards diminishing the burden of HIV worldwide is to ‘test and treat’. In India, almost one quarter of PLHIV are unaware of their HIV status7. HIV-positive individuals continue to be detected late in the course of disease progression, with 85 per cent registering for ART when their CD4 count is already <250 cells/μl, making them vulnerable to AIDS24. Universal testing of the general population every five years, and annual screening among high-risk groups and in high-prevalence districts combined with the expansion of ART services, and earlier ART initiation, will improve outcomes in those with HIV, decrease HIV transmission and improve cost-effectiveness in India. Novel anti-HIV treatment modalities such as potent broadly neutralizing antibodies25 26 and advances in understanding new ways to strengthen the immune system by modifying how immune cells use energy27 will be the key to mitigate for scenarios in which viral resistance threatens virologic responses to the current ART regimen. In India, effective technical support and enhanced monitoring with the involvement of local communities, government and health and research organizations is needed to achieve the reductions required to end the HIV and AIDS epidemics as a public health threat by 2030. At the moment, Australia is one of the few countries that will surpass the ambitious UNAIDS target of ‘90-90-90’ by 2020. Effective Australian Health Promotion Policy that was able to contain the epidemic in Australia included the following efforts28: (i) Health promotion programmes involving the affected communities in discussion and debate about the range and nature of measures it could take to reduce the impact of the epidemic; (ii) Engagement with HIV-positive people for all phases of programme design, from initial concept through the development of content and delivery; and (iii) Campaigns targeting high-risk behaviours rather than high-risk groups. Over the past decade, India has made a significant progress in tackling its HIV epidemic. For ongoing improvement in HIV response, India needs an effective prevention programme (PrEP), protection against discrimination, reduced stigma, strong leadership and advocates, greater access to routine HIV screening and, most importantly, treatment and optimum patient care (Figure). Figure Getting to zero: A multifaceted approach consisting of optimal healthcare delivery, strengthening peer support, technological advances and biomedical interventions. PLHIV, people living with HIV; PrEP, pre-exposure prophylaxis; VL, viral load.
                Bookmark

                Author and article information

                Journal
                Indian J Med Res
                Indian J. Med. Res
                IJMR
                The Indian Journal of Medical Research
                Wolters Kluwer - Medknow (India )
                0971-5916
                December 2019
                : 150
                : 6
                : 515-517
                Affiliations
                [1]School of Public Health, Level 2, Public Health Building, The University of Queensland, Herston QLD 4006, Australia c.gilks@ 123456uq.edu.au
                Article
                IJMR-150-515
                10.4103/ijmr.IJMR_2526_19
                7038813
                32048613
                045a529d-cecc-4e86-8419-a2f0a2220ac9
                Copyright: © 2020 Indian Journal of Medical Research

                This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

                History
                : 03 December 2019
                Categories
                Editorial

                Medicine
                Medicine

                Comments

                Comment on this article